NGNE Quote, Financials, Valuation and Earnings

CEL-SCI has a net margin of -1999.14% compared to Neurogene's net margin of --. Neurogene's return on equity of -- beat CEL-SCI's return on equity of --.

Neurogene has a consensus price target of $52.80, signalling upside risk potential of 134.67%. On the other hand CEL-SCI has an analysts' consensus of -- which suggests that it could grow by 1007.93%. Given that CEL-SCI has higher upside potential than Neurogene, analysts believe CEL-SCI is more attractive than Neurogene.

Neurogene has a beta of 1.235, which suggesting that the stock is 23.528% more volatile than S&P 500. In comparison CEL-SCI has a beta of 0.593, suggesting its less volatile than the S&P 500 by 40.711%.

Neurogene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurogene pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Neurogene quarterly revenues are $925K, which are larger than CEL-SCI quarterly revenues of --. Neurogene's net income of -$20.2M is lower than CEL-SCI's net income of -$6.9M. Notably, Neurogene's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurogene is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of -1999.14% compared to Neurogene's net margin of -416.75%. Neurogene's return on equity of -- beat IGC Pharma's return on equity of -137.43%.

Neurogene has a consensus price target of $52.80, signalling upside risk potential of 134.67%. On the other hand IGC Pharma has an analysts' consensus of -- which suggests that it could grow by 903.48%. Given that IGC Pharma has higher upside potential than Neurogene, analysts believe IGC Pharma is more attractive than Neurogene.

Neurogene has a beta of 1.235, which suggesting that the stock is 23.528% more volatile than S&P 500. In comparison IGC Pharma has a beta of 1.288, suggesting its more volatile than the S&P 500 by 28.8%.

Neurogene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurogene pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

Neurogene quarterly revenues are $925K, which are larger than IGC Pharma quarterly revenues of $412K. Neurogene's net income of -$20.2M is lower than IGC Pharma's net income of -$1.7M. Notably, Neurogene's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurogene is -- versus 21.86x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -1999.14% compared to Neurogene's net margin of -49.65%. Neurogene's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Neurogene has a consensus price target of $52.80, signalling upside risk potential of 134.67%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 620.92%. Given that NovaBay Pharmaceuticals has higher upside potential than Neurogene, analysts believe NovaBay Pharmaceuticals is more attractive than Neurogene.

Neurogene has a beta of 1.235, which suggesting that the stock is 23.528% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Neurogene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurogene pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Neurogene quarterly revenues are $925K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Neurogene's net income of -$20.2M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Neurogene's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurogene is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Ventyx Biosciences has a net margin of -1999.14% compared to Neurogene's net margin of --. Neurogene's return on equity of -- beat Ventyx Biosciences's return on equity of --.

Neurogene has a consensus price target of $52.80, signalling upside risk potential of 134.67%. On the other hand Ventyx Biosciences has an analysts' consensus of $11.14 which suggests that it could grow by 374.16%. Given that Ventyx Biosciences has higher upside potential than Neurogene, analysts believe Ventyx Biosciences is more attractive than Neurogene.

Neurogene has a beta of 1.235, which suggesting that the stock is 23.528% more volatile than S&P 500. In comparison Ventyx Biosciences has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Neurogene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ventyx Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurogene pays -- of its earnings as a dividend. Ventyx Biosciences pays out -- of its earnings as a dividend.

Neurogene quarterly revenues are $925K, which are larger than Ventyx Biosciences quarterly revenues of --. Neurogene's net income of -$20.2M is higher than Ventyx Biosciences's net income of -$35.2M. Notably, Neurogene's price-to-earnings ratio is -- while Ventyx Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurogene is -- versus -- for Ventyx Biosciences. Usually stocks with elevated PS ratios are considered overvalued.